CAR-MA Cytokine Release Assay Service

In CAR-M therapy, the strategic secretion of a broad spectrum of cytokines is central to orchestrating a multifaceted antitumor response, directly mediating efficacy by recruiting adaptive immune cells and reshaping the immunosuppressive tumor microenvironment. Creative Biolabs' CAR-MA Cytokine Release Assay Service employs advanced multiplex immunoassays to deliver precise quantification of this critical functional output. Our service advantage lies in customized profiling panels, which ensure high sensitivity, specificity, and throughput for uncompromising data quality tailored to specific research and development objectives. We ultimately empower your program by delivering actionable insights for candidate selection.

Introduction

As pivotal sentinels of the innate immune system, macrophages are a primary source of diverse cytokines, orchestrating both inflammatory and regulatory immune responses. In the context of chimeric antigen receptor macrophage (CAR-MA) therapy, this inherent capability is strategically harnessed, where upon tumor antigen recognition, engineered CAR-MA cells secrete a spectrum of inflammatory cytokines that directly mediate antitumor efficacy by recruiting and activating adaptive immune cells and remodeling the immunosuppressive tumor microenvironment. Consequently, the quantitative detection of cytokine release is indispensable for the functional validation, potency assessment, and translational development of CAR-MA therapeutics, serving as a critical biomarker for their activation status and mechanistic depth.

Fig.1 Multimodal mechanism of action of CAR-Macrophages.¹

CAR-MA Cytokine Release Assay Service at Creative Biolabs

Creative Biolabs' CAR-MA Cytokine Release Assay Service employ robust, quantitative immunoassays to accurately measure immune cell activity, providing crucial functional data for candidate assessment. Our scientists work in close partnership with you, from mechanism of action studies to preclinical evaluation, to establish the most relevant and informative testing protocol for your therapeutic molecule, ensuring robust data generation at every stage.

What We Can Offer

We offer a suite of sophisticated detection methods designed to address diverse experimental needs. Our customizable cytokine detection panels provide high sensitivity, specificity, and throughput, ensuring reliable data quality for your specific research objectives.

Our Service Process

Required starting materials:

• CAR-MA Construct: The engineered macrophage product, or the viral vector/genetic material used for modification.
• Target Antigen Information: Detailed information on the specific tumor antigen being targeted.
• Dose Range: Proposed concentration range of the CAR-MA product for in vitro testing.

Key Steps Involved:

Final Deliverables:

• Detailed Regulatory Report.
• Raw Data Package.
• Risk Assessment Profile: Clear graphical representation of dose-response curves for key regulatory cytokines and the determined therapeutic window.

Key Advantages

• Advanced Multiplexing Power: We utilize high-content platforms to perform a simultaneous and ultra-sensitive detection of up to 100 inflammatory and anti-inflammatory biomarkers from a minimal sample volume.
• CAR-M Specific Protocol Optimization: We have protocols tailored specifically for CAR-Macrophage constructs to accurately capture macrophage polarization and cytokine/chemokine signatures, which are often missed by T cell focused cytokine release syndrome (CRS) assays.
• Mechanistic and Safety Profiling: We Integrate functional readouts with cytokine quantification to deliver a unified picture of therapeutic efficacy and immunotoxicity, guiding your optimal dose selection.

FAQ

Why Choose Us?

Leveraging comprehensive expertise in advanced cellular platforms and immunotoxicology, Creative Biolabs provides core empowerment for your CAR-MA program. Our CAR-MA Cytokine Release Assay precisely quantifies the therapeutic activity and inflammatory potential of candidate constructs by integrating physiologically relevant cell models and advanced detection technologies. This delivers critical insights into developability and supports de-risking your therapeutic strategy.

Customer Reviews

"Using Creative Biolabs' CAR-MA Cytokine Release Assay Service in our research has significantly improved the confidence in our lead selection. Their ability to simultaneously profile the core regulatory panel alongside T cell-specific cytokines allowed us to clearly differentiate our low-risk CAR-MA from a cytotoxic CAR-T benchmark."— A**am P.

"The formal report provided by Creative Biolabs was a standout deliverable. It clearly addressed our concerns regarding cytokine storm risk, particularly the donor variability and dose-response data, streamlining our submission process considerably."— E**a T.

How to contact us?

Confidently advance your novel CAR-MA therapy by addressing the critical translational bottleneck of CRS. Creative Biolabs provides a specialized CAR-MA Cytokine Release Assay, leveraging cutting-edge multiplex technology and regulatory insights to precisely quantify CRS risk and support the development of a robust preclinical data package. Connect with our team to explore how we can accelerate your immunotherapy's development.

Reference

1. Huang, Ting et al. "CAR-macrophage: Breaking new ground in cellular immunotherapy." Frontiers in cell and developmental biology vol. 12 1464218. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fcell.2024.1464218.